Today 60% of prescriptions filled in Europe up to more than 80% in USA are for generic drugs. In Poland generics represent almost 85% of whole drug market. Nevertheless, a large section of the polish public (including physicians) consider generics to be not as effective as brand name drugs. However, generic drugs are required to have the same active ingredient, strength, dosage form, and route of administration as the brand name products. When a generic drug product is approved, it has met rigorous standards established by the EMA with respect to identity, strength, quality, purity, and potency. Moreover, the generic drug manufacturer must prove its drug is the same (bioequivalent) as the brand name drug. All generic manufacturing, packaging, and testing sites must pass the same quality standards (GMP) as those of brand name drugs, and the generic products must meet the same exacting specifications as brand name products. In fact, many generic drugs are made in the same manufacturing plants as brand name drug products. When it comes to price, there is a big difference between generic and brand name drugs. On average, the cost of a generic drug is often 80 to 85 percent lower than the brand name product. It is possible, because generic manufacturers are not required to repeat the costly clinical trials of new drugs and generally do not pay for costly advertising, marketing, and promotion. This creates competition in the market place, often resulting also in lower prices of the brand name drugs.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/31200 must be provided.

1. Synthesis of new 5H-indolo[2,3-b]quinoline derivatives with a high selective cytotoxic activity
2. 5H-indolo-[2,3-b]quinolines loaded polymeric micelles
3. Efficient preparation of a key intermediate in the exemestane synthesis
4. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
5. Determination of reaction progress in synthesis of EE-3 by NMR technique
6. Optimization of BR-8 synthesis
7. New amino acid and peptide derivatives of 5H-indolo[2,3-b]quinoline and their biological activity.
8. Searching for lead molecules as potential new CNS agents in the serotonin 5-HT₆ screening assay
9. New amino acid derivatives of 6H-indolo[2,3-b]quinolines